Purpose of Technology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that target and inactivate the PCSK9 protein in the liver. This drug is intended to reduce the amount of harmful low-density lipoprotein cholesterol (LDL-C) circulating in the bloodstream, thus lowering patient risk for cardiovascular disease (CVD).
Relevant Questions
-
Is evolocumab effective in lowering cholesterol and decreasing cardiovascular risk?
-
Is evolocumab safe?
-
What is the comparative effectiveness of evolocumab with ezetimibe?
-
Have definitive patient selection criteria been established for patients with hypercholesterolemia or hyperlipidemia treated with evolocumab?
If you have a Hayes login, click here to view the full report on the Knowledge Center.